EFFECT OF BASELINE IBS-C SEVERITY ON ADEQUATE RELIEF: RESULTS FROM A PHASE 2 TRIAL OF LINACLOTIDE

(1) Research and Development, Ironwood Pharmaceuticals, Cambridge

(2) Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, United States



This item was part of the Therapeutic insights in functional digestive disorders session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A96

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2009